|
BK-NM-AMT
BK-NM-AMT, or βk-NM-αMT, also known as β-keto-''N''-methyl-αMT or α,''N''-dimethyl-β-ketotryptamine, as well as 3-indoylmethcathinone, is a serotonin–dopamine releasing agent (SDRA) and putative entactogen of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families. Along with certain other tryptamines, such as α-ethyltryptamine (αET), 5-chloro-αMT and 5-fluoro-αET, it is one of the few SDRAs known. The drug is the ''N''-methyl and β- keto analogue of α-methyltryptamine (αMT). It is a cathinone-like tryptamine and can be thought of as the tryptamine or indole analogue of the phenethylamine methcathinone. The values of BK-NM-AMT for monoamine release are 41.3nM for serotonin and 92.8nM for dopamine in rat brain synaptosomes, whereas it only induced 55% release of norepinephrine at a concentration of 10μM. Several 5-halogenated derivatives of BK-NM-AMT have also been described. These include BK-5F-NM-AMT, BK-5Cl-NM-AMT, and BK-5Br-NM-AMT. Like BK ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonin–dopamine Releasing Agent
A serotonin–dopamine releasing agent (SDRA) is a type of drug which induces the synapse, release of serotonin and dopamine in the body and/or brain. SDRAs are rare, as it has proven extremely difficult to dissociate dopamine and norepinephrine release. However, in 2014, the first selective SDRAs, a series of substituted tryptamines, albeit also acting as serotonin receptor agonists, were described. A closely related type of drug is a serotonin–dopamine reuptake inhibitor (SDRI), for instance UWA-101 (α-cyclopropyl-MDMA). Examples of SDRAs A number of tryptamine chemical derivative, derivatives, specifically substituted α-alkyltryptamine, α-alkyltryptamines, have been found to act as SDRAs. One such agent is 5-chloro-αMT (PAL-542), which has been reported as having about 64-fold selectivity for dopamine release over norepinephrine release and about 3-fold selectivity for serotonin release over dopamine release, making it a highly selective and well-balanced SDRA. Anothe ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Monoamine Releasing Agent
A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of one or more monoamine neurotransmitters from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitters and hence enhanced signaling by those neurotransmitters. The monoamine neurotransmitters include serotonin, norepinephrine, and dopamine; MRAs can induce the release of one or more of these neurotransmitters. MRAs work by reversing the direction of the monoamine transporters (MATs), including the serotonin transporter (SERT), norepinephrine transporter (NET), and/or dopamine transporter (DAT), causing them to promote efflux of non-vesicular cytoplasmic monoamine neurotransmitter rather than reuptake of synaptic monoamine neurotransmitter. Many, but not all MRAs, also reverse the direction of the vesicular monoamine transporter 2 (VMAT2), thereby additionally resulting in efflux of vesicular monoamine neuro ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Substituted Tryptamine
Substituted tryptamines, or simply tryptamines, also known as serotonin analogues (i.e., 5-hydroxytryptamine analogues), are organic compounds which may be thought of as being derived from tryptamine itself. The molecular structures of all tryptamines contain an indole ring, joined to an amino group, amino (NH2) group via an ethyl (−CH2–CH2−) side chain, sidechain. In substituted tryptamines, the indole ring, sidechain, and/or amino group are modified by substituting another group for one of the hydrogen (H) atoms. Well-known tryptamines include serotonin, an important neurotransmitter, and melatonin, a hormone involved in regulating the sleep-wake cycle. Tryptamine alkaloids are found in fungi, plants and animals; and sometimes used by humans for the neurological or psychotropic effects of the substance. Prominent examples of tryptamine alkaloids include psilocybin (from "psilocybin mushrooms") and dimethyltryptamine, DMT. In South America, dimethyltryptamine is obtained f ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Entactogen
Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observed and reported for experiences with MDMA. This class of drug is distinguished from the classes of hallucinogens or psychedelics and stimulants, although entactogens, for instance MDMA, can also have these properties. Entactogens are used both as recreational drugs and are being investigated for medical use in the treatment of psychiatric disorders, for instance MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Notable members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, αMT, αET, and MDAI, among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its cou ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tactogen
Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines. Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions. Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020. Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO). Drug candidates Tactogen has patented various novel entactogen-like compounds from different chemical families. These include benzofurans like 5-MAPB, 5-MBPB, and BK-5-MAPB, benzothiophenes like 5-MAPBT, α-alkyltryptamines like BK-NM-AMT and BK-5F-NM-AMT, indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O, 2-aminoindanes like "BFAI", and non-racemic mixtures of enantiomers. It also has several dru ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BK-5F-NM-AMT
BK-5F-NM-AMT, or βk-5F-NM-αMT, also known as β-keto-5-fluoro-''N''-methyl-αMT or α,''N''-dimethyl-5-fluoro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families. It is known to induce the release of serotonin and dopamine, with respective values of 190nM and 620nM in rat brain synaptosomes, whereas norepinephrine release was not reported. In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors. In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI). BK-5F-NM-AMT was first described in the literature by 2023. It was patented by Matthew Baggott and Tactogen as a potential novel entactogen. BK-5F-NM-AMT is the 5- fluoro derivative In mathematics, the derivative is a fundamental tool that quantifies the sensitivity to change of a func ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BK-5Cl-NM-AMT
BK-5Cl-NM-AMT, or βk-5Cl-NM-αMT, also known as β-keto-5-chloro-''N''-methyl-αMT or α,''N''-dimethyl-5-chloro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families. It is known to induce the release of serotonin and dopamine, with respective values of 200nM and 865nM in rat brain synaptosomes, whereas norepinephrine release was not reported. In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors. In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI). BK-5Cl-NM-AMT was first described in the literature by 2023. It was patented by Matthew Baggott and Tactogen as a potential novel entactogen. BK-5Cl-NM-AMT is the 5-chloro derivative of BK-NM-AMT. Other analogues of the drug include BK-5F-NM-AMT BK-5F-NM-AMT, or βk-5F-NM-αMT, also known ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tactogen Inc
Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines. Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions. Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020. Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO). Drug candidates Tactogen has patented various novel entactogen-like compounds from different chemical families. These include benzofurans like 5-MAPB, 5-MBPB, and BK-5-MAPB, benzothiophenes like 5-MAPBT, α-alkyltryptamines like BK-NM-AMT and BK-5F-NM-AMT, indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O, 2-aminoindanes like "BFAI", and non-racemic mixtures of enantiomers. It also has several drugs in its ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BK-5Br-NM-AMT
BK-5Br-NM-AMT, or βk-5Br-NM-αMT, also known as β-keto-5-bromo-''N''-methyl-αMT or α,''N''-dimethyl-5-bromo-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families. It is known to induce the release of serotonin and dopamine, with respective values of 295nM and 2,100nM in rat brain synaptosomes, whereas norepinephrine release was not reported. In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors. In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI). BK-5Br-NM-AMT was first described in the literature by 2023. It was patented by Matthew Baggott and Tactogen as a potential novel entactogen. BK-5Br-NM-AMT is the 5- bromo derivative of BK-NM-AMT. Other analogues of the drug include BK-5F-NM-AMT and BK-5Cl-NM-AMT BK-5Cl-NM-AMT, or βk-5Cl ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
